erdafitinib FGFR2 Fusion, +5 more biomarkers Urothelial Carcinoma Locally advanced, +1 more state Subsequent line erdafitinib targeted therapy
dasatinib + chemotherapy ABL1 Fusion, +7 more biomarkers B-Cell Acute Lymphoblastic Leukemia Consolidation, +1 more context chemotherapy, +1 more drug chemotherapy, +1 more type
erdafitinib FGFR2 Fusion, +5 more biomarkers Urothelial Carcinoma Locally advanced, +3 more states Second line erdafitinib targeted therapy
erdafitinib FGFR2 Fusion, +5 more biomarkers Urothelial Carcinoma Locally advanced, +3 more states Second line erdafitinib targeted therapy
erdafitinib FGFR2 Fusion, +5 more biomarkers Urothelial Carcinoma Locally advanced, +3 more states Subsequent line erdafitinib targeted therapy
Cancer Search
